within Pharmacolibrary.Drugs.ATC.A;

model A04AA04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00024333333333333333,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0063,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0030600000000000002,
    k12             = 7.31,
    k21             = 7.31
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dolasetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting associated with chemotherapy, radiation, and surgery. It is currently approved for medical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>Herndon, AK, et al., &amp; Gustafson, DL (2018). Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats. <i>Journal of feline medicine and surgery</i> 20(8) 721–727. DOI:<a href=\"https://doi.org/10.1177/1098612X17729310\">10.1177/1098612X17729310</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28905667/\">https://pubmed.ncbi.nlm.nih.gov/28905667</a></p></li><li><p>Dimmitt, DC, et al., &amp; Weir, SJ (1998). Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. <i>Journal of clinical pharmacology</i> 38(9) 798–806. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9753207/\">https://pubmed.ncbi.nlm.nih.gov/9753207</a></p></li><li><p>Dimmitt, DC, et al., &amp; Hahne, W (1998). Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate. <i>The Annals of pharmacotherapy</i> 32(1) 39–44. DOI:<a href=\"https://doi.org/10.1345/aph.17134\">10.1345/aph.17134</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9475818/\">https://pubmed.ncbi.nlm.nih.gov/9475818</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AA04;
